Unsynchronized butyrophilin molecules dictate cancer cell evasion of Vγ9Vδ2 T-cell killing

被引:6
|
作者
Wu, Zeguang [1 ]
Lamao, Qiezhong [1 ]
Gu, Meichao [1 ]
Jin, Xuanxuan [1 ]
Liu, Ying [1 ]
Tian, Feng [1 ]
Yu, Ying [1 ]
Yuan, Pengfei [2 ]
Gao, Shuaixin [3 ]
Fulford, Thomas S. [4 ]
Uldrich, Adam P. [4 ,5 ]
Wong, Catherine C. L. [6 ]
Wei, Wensheng [1 ]
机构
[1] Peking Univ, Genome Editing Res Ctr,State Key Lab Prot & Plant, Biomed Pioneering Innovat Ctr,Sch Life Sci, Beijing Adv Innovat Ctr Genom,Peking Tsinghua Ctr, Beijing 100871, Peoples R China
[2] EdiGene Inc, Life Sci Pk, Beijing 102206, Peoples R China
[3] Peking Univ, Hlth Sci Ctr, Ctr Precis Med Multi Res, Beijing 100191, Peoples R China
[4] Univ Melbourne, Dept Microbiol & Immunol, Peter Doherty Inst Infect & Immun, Parkville, Vic 3010, Australia
[5] Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic, Australia
[6] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, State Key Lab Complex Severe & Rare Dis, Dept Med Res Ctr,Clin Res Inst,Peking Tsinghua Ctr, Beijing 100871, Peoples R China
基金
中国国家自然科学基金;
关键词
Butyrophilin; V gamma 9V delta 2 T-cell; Cancer-specific immune evasion; Glutaminyl-peptide cyclotransferase-like; Pyrophosphate metabolite; Immunotherapy; PHOSPHORYLATED ANTIGENS; ACTIVATION; GENES; BTN3A1; STIMULATION; RFX; TCR;
D O I
10.1038/s41423-024-01135-z
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
V gamma 9V delta 2 T cells are specialized effector cells that have gained prominence as immunotherapy agents due to their ability to target and kill cells with altered pyrophosphate metabolites. In our effort to understand how cancer cells evade the cell-killing activity of V gamma 9V delta 2 T cells, we performed a comprehensive genome-scale CRISPR screening of cancer cells. We found that four molecules belonging to the butyrophilin (BTN) family, specifically BTN2A1, BTN3A1, BTN3A2, and BTN3A3, are critically important and play unique, nonoverlapping roles in facilitating the destruction of cancer cells by primary V gamma 9V delta 2 T cells. The coordinated function of these BTN molecules was driven by synchronized gene expression, which was regulated by IFN-gamma signaling and the RFX complex. Additionally, an enzyme called QPCTL was shown to play a key role in modifying the N-terminal glutamine of these BTN proteins and was found to be a crucial factor in V gamma 9V delta 2 T cell killing of cancer cells. Through our research, we offer a detailed overview of the functional genomic mechanisms that underlie how cancer cells escape V gamma 9V delta 2 T cells. Moreover, our findings shed light on the importance of the harmonized expression and function of gene family members in modulating T-cell activity.
引用
收藏
页码:362 / 373
页数:12
相关论文
共 50 条
  • [41] Chemotherapy Sensitizes Colon Cancer Initiating Cells to Vγ9Vδ2 T Cell- Mediated Cytotoxicity
    Todaro, Matilde
    Orlando, Valentina
    Cicero, Giuseppe
    Caccamo, Nadia
    Meraviglia, Serena
    Stassi, Giorgio
    Dieli, Francesco
    PLOS ONE, 2013, 8 (06):
  • [42] Vγ9Vδ2-T cells as antigen presenting cells for iNKT cell based cancer immunotherapy
    Werter, Inge M.
    Schneiders, Famke L.
    Scotet, Emmanuel
    Verheul, Henk M. W.
    de Gruijl, Tanja D.
    van der Vliet, Hans J.
    ONCOIMMUNOLOGY, 2014, 3 (09)
  • [43] ABCA1 MEDIATES THE EFFLUX OF EXTRACELLULAR ISOPENTENYL-PYROPHOSPHATE AND THE ACTIVATION OF Vγ9Vδ2 T-CELL
    Sciancalepore, P.
    Castella, B.
    Foglietta, M.
    Kopecka, J.
    Mitro, N.
    Mandili, G.
    Caruso, D.
    Novelli, F.
    Riganti, C.
    Massaia, M.
    HAEMATOLOGICA, 2016, 101 : S43 - S43
  • [44] Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity
    Stephen R. Mattarollo
    Tony Kenna
    Mie Nieda
    Andrew J. Nicol
    Cancer Immunology, Immunotherapy, 2007, 56 : 1285 - 1297
  • [45] Thermal stress strengthen Vγ9Vδ2 T cell cytotoxicity by upregulating cytokine secretion
    Lin, L.
    Chen, Y.
    Wu, Y.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 660 - 660
  • [46] Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity
    Mattarollo, Stephen R.
    Kenna, Tony
    Nieda, Mie
    Nicol, Andrew J.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (08) : 1285 - 1297
  • [47] MECHANISM OF ACTION OF LAVA-051, A BISPECIFIC Vγ9Vδ2 T-CELL ENGAGER (BSTCE), CONFIRMED IN THE CLINICAL SETTING
    Lameris, Roeland
    Ruben, Jurjen
    Roovers, Rob
    Kater, Arnon
    Riedl, Thilo
    Iglesias, Victoria
    Broijl, Annemiek
    Tuinhof, Ilse
    Umarale, Sanjana
    Adang, Anton
    de Gruijl, Tanja
    Parren, Paul
    Winograd, Benjamin
    Van der Vliet, Hans
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A716 - A716
  • [48] Cytokines enhance human Vγ9Vδ2 T-cell TCR-dependent and TCR-independent effector functions
    Field, Kirsty R.
    Wragg, Kathleen M.
    Lee, Wen Shi
    Rigau, Marc
    Uldrich, Adam P.
    Kent, Stephen J.
    Juno, Jennifer A.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2023, 53 (06)
  • [49] Phosphonamidate Prodrugs of a Butyrophilin Ligand Display Plasma Stability and Potent Vγ9 Vδ2 T Cell Stimulation
    Lentini, Nicholas A.
    Foust, Benjamin J.
    Hsiao, Chia-Hung Christine
    Wiemer, Andrew J.
    Wiemer, David F.
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (19) : 8658 - 8669
  • [50] Vγ9Vδ2 T cells in human legionellosis
    Kroca, M
    Johansson, A
    Sjöstedt, A
    Tärnvik, A
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2001, 8 (05) : 949 - 954